Novo Nordisk Trips in the Obesity Race

Novo Nordisk just learned the hard way that in the obesity drug arms race, close is not good enough. A key head-to-head trial showed its next big shot failed to match Eli Lilly’s market leader, and investors responded by knocking about 15% off the stock in a single session.

Novo Nordisk said its experimental once-weekly obesity injection CagriSema delivered 23% average weight loss after 84 weeks in a late stage trial. That compared with 25.5% for Eli Lilly’s tirzepatide, the active ingredient in Zepbound and Mounjaro, in the same study.

The trial was designed to show that CagriSema was at least not inferior to tirzepatide on weight loss. It did not meet that goal.

Novo shares fell sharply, dragging Copenhagen’s benchmark index lower given the company’s heavy weighting. Eli Lilly shares moved higher in early trading as investors read the data as another confirmation that tirzepatide remains the benchmark therapy in obesity.

CagriSema combines semaglutide, the ingredient behind Ozempic and Wegovy, with a newer molecule called cagrilintide. Novo has pitched it as a next-generation product capable of extending and strengthening its leadership in obesity. The company has already filed for U.S. approval and expects a regulatory decision later this year, while signalling that additional trials, including higher dose approaches, are being explored.

The setback lands in the middle of a difficult stretch for Novo. The company has warned that sales and profit growth could decline in 2026 amid lower U.S. prices and intensifying competition. It is also facing patent expiries for key products in some markets and ongoing pressure from copycat versions of semaglutide in the U.S.

And Lilly, for its part, on Monday released a new version of its Zepbound drug with a month’s worse of doses in a single pen, further boosting the stock.

The difference between 23% and 25.5% weight loss looks small on paper. In a market that is rapidly professionalizing and becoming more price sensitive, it is enormous.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.

Obesity drugs are moving from hype to infrastructure. Payers are scrutinizing outcomes, employers are weighing costs, and governments are pushing for lower prices. In that environment, the drug with the cleanest efficacy story has leverage. The one that trails has to negotiate.

Novo helped create this market and briefly became Europe’s most valuable company on the back of it. Then Lilly surged ahead in U.S. prescriptions. CagriSema was supposed to reset the competitive dynamic. It was the narrative that Novo could retake clinical leadership and defend premium positioning even as pricing pressure mounted.

Instead, the trial result reinforces the idea that Lilly’s tirzepatide remains the gold standard. For investors, that matters less because of a single data point and more because of what it implies about the medium-term structure of the market. If Lilly keeps the clinical edge, it keeps negotiating power with payers. If Novo is perceived as second best, it competes harder on price.

Novo has argued that the open-label design of the trial may have favored the better-known, commercially established product. That explanation may be scientifically reasonable. Financial markets are less patient with nuance. When a drug designed to show parity or better comes up short, the conclusion is brutal.

This is also about expectations. Consensus models have baked in meaningful long-term revenue from CagriSema as part of Novo’s next growth wave. When a flagship asset looks less dominant, those models wobble. At the same time, the company is already dealing with lower US prices and rising competition. The cushion that once came from blockbuster momentum is thinner.

The share price reaction reflects a repricing of confidence. Investors are adjusting to a scenario where Novo remains a major player in obesity, but without the aura of clinical superiority that once underpinned its valuation premium.

Regulatory approval will still be important, and CagriSema could yet carve out a substantial share of the market. Label language, real-world data, and follow-up trials will shape how it is positioned against tirzepatide in practice.

Novo’s challenge now is strategic as much as scientific. It needs to show that this result does not define the franchise. That may mean sharper differentiation, better data in specific patient segments, or broader pipeline progress that reduces reliance on a single obesity asset.

For now, the market verdict is clear. In a winner-takes-most race, finishing slightly behind feels a lot like losing.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.